{"nctId":"NCT03553758","briefTitle":"EEG Studies of Ketamine General Anesthesia","startDateStruct":{"date":"2018-11-01","type":"ACTUAL"},"conditions":["Anesthesia"],"count":16,"armGroups":[{"label":"Ketamine","type":"EXPERIMENTAL","interventionNames":["Drug: Ketamine"]}],"interventions":[{"name":"Ketamine","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Between the ages of 18 to 45\n* Normal body weight and habitus, BMI less than or equal to 30\n* Non-smoker\n* American Society of Anesthesiologists (ASA) physical status classification P1\n\nExclusion Criteria:\n\n* Cardiovascular: myocardial infarction, coronary artery disease, peripheral vascular disease, arrhythmia, congestive heart failure, valvular disease, hypertension\n* Respiratory: bronchitis, chronic obstructive pulmonary disease, smoking, shortness of breath\n* Hepatic: hepatitis, jaundice, ascites\n* Neurologic: seizure, stroke, positive neurologic findings on neurologic examination, multiple sclerosis, Meniere's disease, Parkinson's disease, neuropathy, peripheral stenosis\n* Gastrointestinal: esophageal reflux, hiatal hernia, ulcer\n* Endocrine: diabetes, thyroid disease\n* Renal: acute or chronic severe renal insufficiency\n* Hematologic: blood dyscrasias, anemia, coagulopathies, on anticoagulant therapy\n* Musculoskeletal: prior surgery or trauma to head neck or face, arthritis, personal or family history of malignant hyperthermia\n* Psychiatric: history or treatment for an active psychiatric problem, depression\n* Reproductive: pregnancy, breast-feeding\n* Medications: regular use of prescription and non-prescription medications expected to affect CNS function, St. John's Wort\n* Allergies: labetalol, ondansetron, glycopyrrolate, ketamine, midazolam","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","maximumAge":"45 Years","stdAges":["ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Average Pain Intensity Pre- and Post-Ketamine Induction","description":"Average Pain Intensity prior to ketamine induction, 30 minutes post ketamine, 60 minutes post ketamine, 75 minutes post ketamine, and 120 minutes post ketamine. PROMIS Pain Intensity 1a was used to assess pain delivered by a pre-calibrated pain cuff. Scale of 0 (no pain) to 10 (worst imaginable pain).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.9","spread":"0.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.6","spread":"1.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.1","spread":"2.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.3","spread":"2.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.4","spread":"2.3"}]}]}]},{"type":"SECONDARY","title":"Average Dissociation States Score Pre- and Post-Ketamine Induction","description":"Patients were assessed for dissociation states prior to the induction of ketamine and at 60 minutes, 75 minutes, and 120 minutes after Ketamine was administered. The Clinician Administered Dissociation States Scale was used to measure dissociation. Each section is scored 0 (not at all) to 4 (extreme), and totaled. The minimum total score is 0 (best, no dissociation at all) and the maximum total score is 92 (worst, the most dissociation).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":"0.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22.1","spread":"17"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.3","spread":"11.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.2","spread":"7.3"}]}]}]},{"type":"SECONDARY","title":"Difference of the Mean Clinician Administered Dissociative States Scale Before and After Midazolam Administration","description":"Midazolam was administered approximately 60 minutes after the administration of Ketamine in order to reduce the effects of Ketamine on dissociation. Dissociation was measured using the Clinician Administered Dissociative States Scale. Each section is scored 0 (not at all) to 4 (extreme), and totaled. The minimum total score is 0 (best, no dissociation at all) and the maximum total score is 92 (worst, the most dissociation). The difference of the mean Clinician Administered Dissociative States Scale before and after Midazolam administration was found.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.3","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":15},"commonTop":[]}}}